Jane Street Group, LLC Summit Therapeutics Inc. Transaction History

Jane Street Group, LLC

$444 Billion
Q4 2024

A detailed history of Jane Street Group, LLC transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 411,800 shares of SMMT stock, worth $9.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

411,800

Previous 351,151 17.27%

Holding current value

$9.5 Million

Previous $7.69 Million 4.42%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$17.52 - $23.46 $3.79 Million - $5.07 Million	-216,051 Reduced 61.53%	135,100 $2.41 Million
Q3 2024 Nov 14, 2024	BUY	$6.89 - $31.93 $1.13 Million - $5.21 Million	163,306 Added 86.94%	351,151 $7.69 Million
Q2 2024 Aug 14, 2024	BUY	$2.39 - $10.92 $115,542 - $527,916	48,344 Added 34.65%	187,845 $1.47 Million
Q1 2024 May 15, 2024	BUY	$2.55 - $5.07 $76,841 - $152,779	30,134 Added 27.55%	139,501 $577,000
Q4 2023 Feb 14, 2024	BUY	$1.67 - $2.83 $182,642 - $309,508	109,367 New	109,367 $285,000
Q2 2023 Aug 14, 2023	SELL	$1.32 - $2.81 $519,673 - $1.11 Million	-393,692 Reduced 94.84%	21,399 $53,000
Q1 2023 May 15, 2023	BUY	$1.38 - $5.41 $494,641 - $1.94 Million	358,436 Added 632.66%	415,091 $726,000
Q4 2022 Feb 14, 2023	BUY	$0.68 - $5.31 $24,749 - $193,262	36,396 Added 179.65%	56,655 $240,000
Q3 2022 Nov 14, 2022	BUY	$0.89 - $1.63 $18,030 - $33,022	20,259 New	20,259 $24,000
Q1 2022 May 17, 2022	SELL	$2.0 - $3.45 $24,286 - $41,893	-12,143 Closed	0 $0
Q4 2021 Feb 15, 2022	BUY	$2.45 - $5.64 $29,750 - $68,486	12,143 New	12,143 $33,000

Others Institutions Holding SMMT

# of Institutions

232

Shares Held

83.1M

Call Options Held

1.66M

Put Options Held

2.56M

View Full List

About Summit Therapeutics Inc.

Ticker SMMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,215,008
Market Cap $4.64B
Description
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...

More about SMMT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.

Account

Jane Street Group, LLC Summit Therapeutics Inc. Transaction History